What is LDL?
LDL
Low-density lipoprotein (LDL) is a cholesterol-carrying lipoprotein measured in blood and a risk marker for cardiovascular disease. Discussion of it in the supplied material centers on how aggressively it should be lowered and how it compares with other lipid measures as a predictor of cardiovascular events.
How it developed
- Mar 2026 - David Sinclair said the brain does not take cholesterol from the bloodstream and makes its own.
- Sep 2026 - Marios Georgakis said variants that raise HDL without influencing LDL cholesterol do not influence cardiovascular disease risk.
- Sep 2026 - Georgakis said that in the HORIZON trial average baseline LDL was about 65, yet over a median four to five years more than 10% developed new cardiovascular events.
- Sep 2026 - Georgakis said a 100 mg/dL reduction in Lp(a) would be needed for risk reduction comparable to a 40 mg/day LDL cholesterol reduction, which he put at 20 to 25%.
- Sep 2026 - Mark Hyman said 54% of those tested had high ApoB, a lipid biomarker he described as more important than LDL or other cholesterol biomarkers and rarely checked.
In the evidence
Every line below is attributed to a named speaker.
A 100 mg/dL reduction in Lp(a) is needed to match the cardiovascular risk reduction from a 40 mg/dL LDL reduction, roughly 20 to 25 percent.
“We would need a 100 milligrams per deciliter reduction in LP little A to achieve a risk reduction that would be comparable to what we see with 40 milligs per day reduction in LDL cholesterol which would be 20 to 25% risk reduction.”Marios Georgakis · 14 Sep 2026
Mendelian randomization shows HDL is not a causal cardiovascular target: genetic variants that raise HDL without affecting LDL do not reduce cardiovascular disease risk.
“If we find variants that raise HDL but have no influence on LDL cholesterol, they do not influence the risk of cardiovascular disease.”Marios Georgakis · 14 Sep 2026
In the Horizon trial, average baseline LDL was 65 mg/dL yet more than 10 percent of patients developed new cardiovascular events over a median 4 to 5 year follow-up, quantifying large residual risk on modern therapy.
“In horizon average LDL was 65 if I'm not mistaken at baseline and still over the trial duration median four five years more than 10% developed new cardiovascular events.”Marios Georgakis · 14 Sep 2026
According to American College of Cardiology literature, ApoB is a more important cardiovascular risk marker than LDL, yet it is rarely ordered in routine care.
“We're seeing, you know, 54% with high APOB, which is a lipid biomarker that most doctors don't check that is more important than LDL or any other cholesterol biomarker based on the American College of Cardiology literature and yet it's not checked.”Mark Hyman · 4 Sep 2026
The brain synthesizes its own cholesterol independently of the bloodstream, so reducing blood LDL via statins does not deprive the brain of cholesterol.
“It's a little-known fact that the brain doesn't the cholesterol from the bloodstream. It makes its own.”David Sinclair · 23 Mar 2026